Abstract Library

#2265 Activity of Bevacizumab in Neuroendocrine Neoplasms

Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Apostolidis L

Authors: Fejzibegovic N, Jäger D, Winkler E, Apostolidis L,

Keywords: neuroendocrine neoplasm, targeted therapy, bevacizumab, antiangiogenesis,

#2008 Preliminary Evaluation of Influence of Different Targeted Drugs of Vascular Endothelial Growth Factor Signaling Pathway on the Proliferation of Neuroendocrine Neoplasm Cell Lines

Introduction: Sunitinib and bevacizumab are intracellular and extracellular inhibitor of vascular endothelial growth factor(VEGF) pathway respectively, the influence of both of which on the proliferation of neuroendocrine neoplasm (NEN) cell lines in vitro was not known yet.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zhang Y

Authors: Zhang Y, Chen L, Lin Y, Chen M, Chen J,

Keywords: neuroendocrine neoplasm, sunitinib, bevacizumab, VEGF pathway,

#1743 FOLFIRI Regimen with or without Bevacizumab As Second-Line Therapy Showed Activity in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

Introduction: Metastatic disease of GEP-NEC is tough condition in clinical practice. And the role of the second-line therapy remains unknown

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: ZHIYU C

Authors: Chen Z, Zhao X, Wang C, Zhang W, Zhu X,

Keywords: NEC, FOLFIRI, bevacizumab ,

#1094 Experience with Bevacizumab in Neuroendocrine Tumors

Introduction: Bevacizumab has shown promising activity in neuroendocrine tumors (NET) in combination with a multitude of other substances.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Apostolidis L

Authors: Apostolidis L, Jäger D, Winkler E,

Keywords: neuroendocrine tumor, targeted therapy, bevacizumab, anti-angiogenesis,

#912 Serial 89Zr-bevacizumab PET in Patients with Neuroendocrine Tumors before and on Everolimus Treatment

Introduction: Everolimus increases PFS in patients with advanced NETs. Currently, no biomarkers are available for early selection of patients who will benefit from everolimus. Everolimus can reduce VEGF-A production by tumor cells.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Brouwers A, Van Asselt S, Oosting S, De Jong J, Lub-de Hooge M,

Keywords: neuroendocrine tumors, 89Zr-bevacizumab PET, VEGF-A, everolimus, biomarker,